Plain-English translation of NCT04459689 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are gathering information from patients and healthcare providers around the world to understand how COVID-19 affects people with primary immune deficiencies—rare conditions where the immune system doesn't work properly. This is the second phase of a global survey designed to learn about the outcomes and challenges that immunodeficient patients face when infected with COVID-19. The information will help doctors better understand and treat these patients in the future.
When the COVID-19 pandemic began, doctors realized they didn't have enough information about how the virus affects people with primary immune deficiencies, even though these patients may be at higher risk. This study exists to fill that knowledge gap and help doctors understand what happens when immunodeficient patients get COVID-19.
You likely qualify if…
You likely don't qualify if…
Your healthcare provider would enter information about your COVID-19 infection and your primary immune deficiency into a secure, password-protected online platform. You don't need to travel or attend visits—your doctor simply logs in and shares your relevant medical history. The process is designed to take as little time as possible while gathering important details that will help researchers understand how your condition affects COVID-19 illness.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
France
Enrollment target
~200 participants
Started
March 2020
Primary completion
February 2027
Age range
0 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nizar MAHLAOUI, MD, MPH, PhD
Necker Enfants Malades University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.